Research & Development
ViiV Healthcare files lawsuit against Gilead Sciences
12 February 2018 -

United Kingdom-based ViiV Healthcare has filed a lawsuit against Gilead Sciences, alleging that bictegravir contained in the latter's triple combination HIV drug infringes patent covering dolutegravir in the US and Canada, it was reported on Friday.

The product is one of the three drugs utilised in Biktarvy, which received approval from the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

According to the lawsuits filed in the US District Court for the District of Delaware and the Canadian Federal Court in Toronto, the company accused Gilead's bictegravir of not only infringing patent covering dolutegravir but also several other compounds that include the drug's unique chemical scaffold. The company stated that it will seek financial redress for the alleged patent infringement by Gilead's bictegravir.